In silico approaches and chemical space of anti-P-type ATPase compounds for discovering new antituberculous drugs
- PMID: 28111912
- DOI: 10.1111/cbdd.12950
In silico approaches and chemical space of anti-P-type ATPase compounds for discovering new antituberculous drugs
Abstract
Tuberculosis (TB) is one of the most important public health problems around the world. The emergence of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis strains has driven the finding of alternative anti-TB targets. In this context, P-type ATPases are interesting therapeutic targets due to their key role in ion homeostasis across the plasma membrane and the mycobacterial survival inside macrophages. In this review, in silico and experimental strategies used for the rational design of new anti-TB drugs are presented; in addition, the chemical space distribution based on the structure and molecular properties of compounds with anti-TB and anti-P-type ATPase activity is discussed. The chemical space distribution compared to public compound libraries demonstrates that natural product libraries are a source of novel chemical scaffolds with potential anti-P-type ATPase activity. Furthermore, compounds that experimentally display anti-P-type ATPase activity belong to a chemical space of molecular properties comparable to that occupied by those approved for oral use, suggesting that these kinds of molecules have a good pharmacokinetic profile (drug-like) for evaluation as potential anti-TB drugs.
Keywords: Mycobacterium tuberculosis; P-type ATPases; antituberculous targets; chemical space; plasma membrane.
© 2017 John Wiley & Sons A/S.
Similar articles
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.Curr Pharm Des. 2014;20(27):4305-6. doi: 10.2174/1381612819666131118203915. Curr Pharm Des. 2014. PMID: 24245755
-
Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against M. tuberculosis Enzyme Targets.Curr Top Med Chem. 2020;20(29):2662-2680. doi: 10.2174/1568026620666200903163921. Curr Top Med Chem. 2020. PMID: 32885754 Review.
-
Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.Bioorg Med Chem. 2015 Feb 15;23(4):742-52. doi: 10.1016/j.bmc.2014.12.060. Epub 2015 Jan 2. Bioorg Med Chem. 2015. PMID: 25614114
-
Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.Bioorg Med Chem. 2015 Aug 15;23(16):5087-97. doi: 10.1016/j.bmc.2014.12.031. Epub 2014 Dec 24. Bioorg Med Chem. 2015. PMID: 25577708 Review.
Cited by
-
Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis.Indian J Microbiol. 2017 Dec;57(4):371-377. doi: 10.1007/s12088-017-0674-0. Epub 2017 Oct 24. Indian J Microbiol. 2017. PMID: 29151636 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical